SHELBY BARE: Open Payments
NPI 1558979062 · HANOVER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,815 in 95 payments from 26 companies in 2025. Trend: 2023 $2,342 · 2024 $2,652 · 2025 $1,815
Food & beverage: $1,715Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $329 |
| AstraZeneca Pharmaceuticals LP | 11 | $246 |
| ABBVIE INC. | 12 | $160 |
| Astellas Pharma US Inc | 4 | $120 |
| Janssen Biotech, Inc. | 1 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $95 |
| GlaxoSmithKline, LLC. | 5 | $85 |
| Lilly USA, LLC | 4 | $72 |
| Merck Sharp & Dohme LLC | 4 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $62 |
Products named: FARXIGA, Ozempic, Veozah, Wegovy, RYBREVANT, CAPLYTA, TRELEGY ELLIPTA, JARDIANCE.
Industry payments across PA — which companies pay providers there.
